SINGLE-CELL DNA ANALYSIS OF MUTATIONAL HETEROGENEITY IN ACUTE MYELOID LEUKEMIA TUMORS WITH HIGH-THROUGHPUT DROPLET MICROFLUIDICS
EHA Learning Center, Dennis Eastburn, 214633
INFLAMED BM-MSCS HIGHLY ATTRACT TEL-AML1+ PRE-LEUKEMIC CELLS AND PROVIDE A SUSTAINING NICHE FOR THEIR EMERGENCE
EHA Learning Center, Linda Beneforti, 215233
COHESIN GENES MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Grazia Fazio, 215248
EVALUATION OF SAMPLE QUALITY AND CREATION OF DATABASES FOR FOLLOW-UP ASSESSMENT OF BLAST INFILTRATION AT DAY +15 IN CHILDHOOD B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
EHA Learning Center, Pablo Manresa Manresa, 215249
GENETIC ALTERATIONS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN TAIWAN: A COMPARISON BETWEEN PEDIATRIC AND ADULT COHORTS
EHA Learning Center, Ying-Jung Huang, 215250
THE RISK OF DEVELOPING HEPATIC TOXICITY FROM PEGYLATED-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS HIGHLY AFFECTED BY CONCOMITANT MEDICATIONS
EHA Learning Center, Paola Minetto, 215265
CELL OF ORIGIN INFLUENCES DISEASE AGGRESSIVENESS AND CHEMOTHERAPY RESISTANCE IN A MOUSE MODEL OF MLL-AF9 REARRANGED ACUTE MYELOID LEUKEMIA
EHA Learning Center, Chi Nguyen, 215266
PLASMA PROTEOME IN PATIENTS WITH LEUKEMIA AND LYMPHOMA REVEALS MAJOR DIFFERENCES RELATED TO HEMOSTASIS, INFLAMMATION AND STROMA
EHA Learning Center, Anna Eriksson, 215267
TARGETED THERAPY FOR AML EXPRESSING SOMATIC OR GERMLINE MUTATION IN RUNX1
EHA Learning Center, Kapil Bhalla, 215281
DECIPHERING THE GENETIC LANDSCAPE OF ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING
EHA Learning Center, Frank Rücker, 215282
PHOSPHO-PROFILING LINKING AML-BIOLOGY AND RESPONSE PREDICTION IN PEDIATRIC MYELOID LEUKEMIA
EHA Learning Center, Michaela Prchal-Murphy, 215283
MOLECULAR ABNORMALITIES IN THERAPY-RELATED ACUTE MYELOID LEUKEMIAS
EHA Learning Center, Gueorgui Balatzenko, 215298
CD123 REDIRECTED NK92 CELLS FOR ACUTE MYELOID LEUKEMIA
EHA Learning Center, Li Zhou, 215299
THE DIFFERENTIAL EXPRESSION OF DNMT3A SPLICE VARIANTS AND THEIR PROGNOSTIC RELEVANCE IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Stefanie Beinicke, 215300
ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA
EHA Learning Center, Neena Kapoor, 215314
COMPARISON BETWEEN MULTIPARAMETRIC FLOW CYTOMETRY AND RT-QPCR ASSAY IN EVALUATING MINIMAL RESIDUAL DISEASE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IN NPM1 ACUTE MYELOID LEUKEMIA
EHA Learning Center, Chiara Caprioli, 215315
MRD STATUS AT TRANSPLANTATION IN SECOND OR THIRD CR IS THE STRONGEST FACTOR AFFECTING THE PROBABILITY OF RELAPSE IN AML PATIENTS
EHA Learning Center, Fabio Guolo, 215316
TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE.
EHA Learning Center, Giovanni Marconi, 215330
ADDITION OF BORTEZOMIB TO AML-LIKE TREATMENT FOLLOWED BY NMA ALLO-SCT IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
EHA Learning Center, Elisabeth Tolley, 215331
BLAST TRANSFORMATION IN MYELODYSPLASTIC AND MYELOPROLIFERATIVE NEOPLASMS - SIMILARITIES AND DIFFERENCES - A REVIEW OF 100 CASES
EHA Learning Center, Milan Jagurinoski, 215332
EXCELLENT OUTCOMES OF OLDER PATIENTS WITH PCNSL USING R-MPV/ARA-C IMMUNOCHEMOTHERAPY WITHOUT WHOLE BRAIN RADIOTHERAPY (WBRT)
EHA Learning Center, Gareth Gregory, 215346
FIRST REPORT ON A SUCCESSFUL SCREENING PROGRAM FOR MYC REARRANGEMENTS AND A PROSPECTIVE CLINICAL TRIAL BASED ON MYC REARRANGEMENT IN NEWLY DIAGNOSED DLBCL PATIENTS IN THE NETHERLANDS
EHA Learning Center, Martine Chamuleau, 215347
A NOVEL IMMUNOHISTOCHEMICAL PROGNOSTIC SCORE BASED ON MYC, BCL2 AND BCL6 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RETROSPECTIVE ANALYSIS OF DE NOVO DLBCL TREATED WITH RITUXIMAB-CHOP
EHA Learning Center, Mattia Novo, 215348
THE IMPACT OF DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS ON SURVIVAL OUTCOMES IN 131 NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
EHA Learning Center, Gayane Tumyan, 215362
TREATMENT OF TRAUMATIC BLEEDS WITH RECOMBINANT FACTOR XIII-A2 IN PATIENTS WITH CONGENITAL FXIII-A SUBUNIT DEFICIENCY: RESULTS FROM THE MENTOR™6 STUDY
EHA Learning Center, Jolanta Klovaite, 215363
BEVACIZUMAB SIGNIFICANTLY IMPROVES SEVERE EPISTAXIS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA
EHA Learning Center, Silva ZUPANCIC SALEK, 215364
PHASE 2 STUDY OF X4P-001: A TARGETED ORAL THERAPY FOR PATIENTS WITH WHIM SYNDROME
EHA Learning Center, David Dale, 215378
SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA.
EHA Learning Center, Iris Nederlof, 215379
RESULTS OF HEMATOPOIETIC STEM CELLS TRANSPLANTATION IN CONGENITAL BONE MARROW FAILURE SYNDROMES: SINGLE CENTER EXPERIENCE WITH FOCUS ON TCR ΑΒ+/CD19+ DEPLETION
EHA Learning Center, Zhanna Shekhovtsova, 215380
DEVELOPMENT OF SELECTIVE CASEIN KINASE 1 DELTA/EPSILON INHIBITORS FOR CANCER THERAPY
EHA Learning Center, Michaela Gregorova, 215394
NEXT-GENERATION SEQUENCING AND CRISPR/CAS9 APPLICATION TO ELUCIDATE THE IMPLICATIONS OF TP53 MUTATIONS IN DEL(13Q) CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 215396
ENCYCLOPEDIA OF CLL SUBSETS: AN ONLINE KNOWLEDGEBASE FOR SUBSETS OF CLL CASES WITH STEREOTYPED B CELL RECEPTORS
EHA Learning Center, Tomas Reigl, 215397
SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 27 NEW CASES FROM THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) INTERNATIONAL REGISTRY
EHA Learning Center, Ilaria Del Giudice, 215411
A PROGNOSTIC TOOL FOR THE IDENTIFICATION OF EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AT IMMINENT RISK OF PROGRESSION
EHA Learning Center, Lodovico Terzi di Bergamo, 215412
SURVIVAL CONTINUES TO INCREASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED ANALYSIS AMONG 19,131 PATIENTS DIAGNOSED IN THE NETHERLANDS BETWEEN 1989 AND 2015
EHA Learning Center, Lina van der Straten, 215413
OPTIMAL TIME POINT FOR BCR-ABL1 KD MUTATION ANALYSIS IN CML PATIENTS; BASED ON 2013 ELN GUIDELINE
EHA Learning Center, Young Rok Do, 215427
CLONAL SELECTION DETERMINES RESULTANT DOMINANCE OF TYROSINE KINASE INHIBITOR-RESISTANT CELLS IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Benjamin Leow, 215428
WT1 ANALYSIS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
EHA Learning Center, Sabrina COLUZZI, 215429
IMATINIB STOP STUDY FEASIBLE TO JAPANESE CLINICAL SETTING.
EHA Learning Center, Kensuke Usuki, 215443
THE TARGET UK STUDY: AN EVALUATION OF TYROSINE KINASE INHIBITOR RESPONSE MONITORING PATTERNS AND REAL-WORLD MOLECULAR RESPONSE RATES IN UK PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Adam Mead, 215444
THE OCCURRENCE AND SURVIVAL OF COLD AGGLUTININ DISEASE IN DENMARK
EHA Learning Center, Sigbjørn Berentsen, 215445
THE REDUCTION OF GRAFT-VERSUS-HOST DISEASE AND TRANSFUSIONAL NEEDS AFTER THE APPLICATION OF MESENCHYMAL STEM CELL THERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hajnalka Andrikovics, 215460
IMMUNOGENICITY OF TISAGENLECLEUCEL IN RELAPSED/ REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS
EHA Learning Center, Theodore Laetsch, 215461
CONSIDERATIONS FOR TISAGENLECLEUCEL DOSING RATIONALE
EHA Learning Center, Rakesh Awasthi, 215462
TELOMERASE TRANSCRIPTS FLOATING IN CANCER-DERIVED EXOSOMES REPROGRAM THE MICRORNA TRANSCRIPTOME PROFILE OF THE RECIPIENT CELLS
EHA Learning Center, Daniela Likonen, 215476
ALTERATIONS IN STROMAL PRECURSOR CELLS IN THE BONE MARROW OF PATIENTS WITH LEUKEMIA IN THE ONSET OF THE DISEASE AND AFTER TREATMENT
EHA Learning Center, Nataliya Petinati, 215477
LYMPHOPENIA AND RISK OF INFECTIONS AND INFECTION-RELATED DEATH IN DENMARK, 2003-2013: A PROSPECTIVE COHORT STUDY OF 98,344 INDIVIDUALS FROM THE GENERAL POPULATION
EHA Learning Center, Marie Warny, 215478
IBRUTINIB SHOWS PROLONGED PROGRESSION-FREE SURVIVAL IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH MYD88 MUTATED WALDENSTROM'S MACROGLOBULINEMIA: LONG-TERM FOLLOW-UP OF PIVOTAL TRIAL (NCT01614821).
EHA Learning Center, Steven Treon, 215492
IMPROVED DEPTH OF RESPONSE WITH INCREASED FOLLOW-UP FOR PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH BRUTON’S TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB
EHA Learning Center, Judith Trotman, 215493
CHARACTERIZATION OF MALT LYMPHOMA WITH T(11;18): LONG-TERM FOLLOW-UP
EHA Learning Center, Kosuke Toyoda, 215494
COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA (MDRB) IS ASSOCIATED WITH COMPLICATIONS AND POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
EHA Learning Center, Chiara Maria DELLACASA, 215509
ANTIBIOTICS CAN SAFELY BE DISCONTINUED IN NEUTROPENIC HEMATOLOGY PATIENTS: A PROSPECTIVE COHORT
EHA Learning Center, Zoe Van de Wyngaert, 215510
RISK OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE ERA OF NOVEL THERAPIES: A RETROSPECTIVE SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Francesco Autore, 215511
HEMATOPOIETIC IMPROVEMENT AFTER DEFERASIROX TREATMENT IN A CHILD WITH APLASTIC ANEMIA
EHA Learning Center, Gizem Ersoy, 215526
TREATMENT WITH FERRIC CARBOXYMALTOSE FOR SEVERE IRON DEFICIENCY ANEMIA IN STABLE NOT ACTIVELY BLEEDING PATIENTS IN THE EMERGENCY DEPARTMENT
EHA Learning Center, Irene Motta, 215527
IRON DEFICIENCY ANAEMIA – ZINC PROTOPORPHYRIN, A SIMPLE, FAST, INEXPENSIVE DIAGNOSTIC METHOD
EHA Learning Center, João Gomes, 215528
EXPRESSION LEVEL OF SPECIFIC MIRNAS BEFORE AZACITIDINE THERAPY INITIATION MAY PREDICT FUTURE EFFICACY OF THE TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
EHA Learning Center, Michaela Dostalova Merkerova, 215542
MULTICENTRIC VALIDATION OF THE “MONOCYTE ASSAY” FOR CHRONIC MYELOMONOCYTIC LEUKEMIA DIAGNOSIS BY FLOW CYTOMETRY
EHA Learning Center, Orianne Wagner-Ballon, 215543
CHARACTERIZATION AND DIFFERENTIAL EFFECTS OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Manja Wobus, 215544
CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY.
EHA Learning Center, Panagiotis Diamantopoulos, 215558
OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND STABLE DISEASE DURING TREATMENT WITH AZACITIDINE: A REPORT FROM GRUPPO ROMANO MIELODISPLASIE (GROM) AND RETE EMATOLOGICA LOMBARDA (REL).
EHA Learning Center, Luca Maurillo, 215559
PREDICTIVE FACTORS OF OVERALL SURVIVAL AND TREATMENT RESPONSE IN HIGH-RISK OLDER PATIENTS WITH MDS AND CMML UNDER HYPOMETHILATING AGENTS. LATIN-AMERICAN MDS GROUP - GLAM
EHA Learning Center, Marcelo Iastrebner, 215560
GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION
EHA Learning Center, Paola Minetto, 215575
MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN MULTIPLE MYELOMA RESISTANCE
EHA Learning Center, Alejandra Ortiz, 215576
ELOTUZUMAB PROMOTES SELF-ENGAGEMENT OF SLAMF7 BETWEEN NATURAL KILLER AND MULTIPLE MYELOMA CELLS TO ENHANCE CYTOTOXICITY
EHA Learning Center, Michael D. Robbins, 215577
ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL
EHA Learning Center, Matthew Jenner, 215591
POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE-BASED TREATMENT FAILURE
EHA Learning Center, David S. Siegel, 215592
DOUBLET VS TRIPLET LENALIDOMIDE-CONTAINING REGIMENS FOLLOWED BY MAINTENANCE: SUBGROUP ANALYSIS BY FRAILTY STATUS AFTER A MEDIAN FOLLOW-UP OF 5 YEARS (EMN01 PHASE III STUDY)
EHA Learning Center, Sara Bringhen, 215593
CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN NORTH AMERICA AND EUROPE: FINDINGS FROM THE PREAMBLE STUDY
EHA Learning Center, Ravi Vij, 215607
COMPLETE RESPONSE AND INDUCTION TREATMENT DOES NOT AFFECT SURVIVAL IN MYELOMA PATIENTS RELAPSING WITHIN 18 MONTHS FOLLOWING UP-FRONT HDM-ASCT. A POPULATION-BASED STUDY FROM 1994 TO 2015
EHA Learning Center, Annette Vangsted, 215608
THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS
EHA Learning Center, Tobias Klausen, 215623
COMPARISON OF LYMPHOTRACK® MISEQ® ASSAYS AND FLOW CYTOMETRY FOR CLONALITY AND MINIMUM RESIDUAL DISEASE ASSESSMENT IN MULTIPLE MYELOMA
EHA Learning Center, Austin Jacobsen, 215624
LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Qaiser Bashir, 215639
THE SCREENING OF PROTEINS SIGNATURES WITH SIGNALING PATHWAY IN POLYCYTHEMIA VERA AND INHIBITION OF PIM ENHANCES JAK2 INHIBITOR SENSITIVITY
EHA Learning Center, Wuhan Hui, 215640
GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT
EHA Learning Center, Daniela Barraco, 215655
TARGETED TREATMENT WITH DIVERSE TYROSINE KINASE INHIBITORS IN PATIENTS WITH PCM1-JAK2, BCR-JAK2 AND ETV6-ABL1 POSITIVE EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS
EHA Learning Center, Georgia Metzgeroth, 215656
PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS
EHA Learning Center, Bozena Sokolowska, 215671
SECOND MALIGNANCIES IN HIDROXYUREA AND INTERFERON TREATED PATIENTS
EHA Learning Center, Telma Domingues, 215672
NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT’S LYMPHOMA CELLS
EHA Learning Center, Jianda Hu, 215688
DOMINANT CYTOTOXIC NK CELL SUBSET WITHIN CLPD-NK PATIENTS IDENTIFIES A MORE AGGRESSIVE NK CELL PROLIFERATION
EHA Learning Center, Gregorio Barilà, 215689
EVALUATION OF HIT SYNDROME WITH AN AUTOMATED IMMUNOASSAY IN CORRELATION WITH THE 4T SCORE IN CARDIOVASCULAR PATIENTS
EHA Learning Center, Theoni Kanellopoulou, 215705
IMMATURE PLATELET FRACTION AS A MARKER OF THROMBOPOIESIS IN THROMBOCYTOPENIC PATIENTS
EHA Learning Center, David J Camilleri, 215706
IMPACT OF CMV PROPHYLAXIS ON RATES OF REHOSPITALIZATION IN ADULT CMV SEROPOSITIVE ALLOGENEIC HSCT RECIPIENT: EXPERIENCE FROM THE LETERMOVIR PHASE 3 CLINICAL TRIAL
EHA Learning Center, Jonathan SCHELFHOUT, 215722
QUALITY OF LIFE IN PATIENTS WITH RARE HEREDITARY HEMOLYTIC ANEMIA, THE IMPORTANCE OF SOCIAL SUPPORT
EHA Learning Center, Stephanie van Straaten, 215723
HEME-INDUCIBLE LIPID OXIDATION PATTERN SUPPORTS MONITORING OF CELL-FREE HEMOGLOBIN ACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE.
EHA Learning Center, Jeremy Deuel, 215738
COMPLEMENT ACTIVATION IN HOMOZYGOUS SICKLE CELL DISEASE PATIENTS IS MODULATED BY HYDROXYUREA
EHA Learning Center, Lubka Roumenina, 215739
ASSOCIATION OF SOCIO-ECONOMIC FACTORS WITH SURVIVAL OF PATIENTS WHO EXPERIENCE SEVERE CLASSIC ACUTE GVHD AFTER ALLO-HSCT. A RETROSPECTIVE STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY, EBMT
EHA Learning Center, Andrzej Frankiewicz, 215755
COMPARISON OF REDUCED-INTENSITY CONDITIONING REGIMENS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA > 45 YEARS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A RETROSPECTIVE STUDY BY THE ALWP/EBMT
EHA Learning Center, Zinaida Peric, 215756
PROGNOSTICATION OF CHRONIC GRAFT VERSUS HOST DISEASE: THE IMPACT OF IMMUNE RECONSTITUTION.
EHA Learning Center, Fabio Serpenti, 215771
UTILIZATION AND OUTCOMES OF FERTILITY PRESERVATION TECHNIQUES IN WOMEN UNDERGOING ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT
EHA Learning Center, Alexandra Higgins, 215772
SELECTIVE INHIBITION OF OXIDATIVE PHOSPHORYLATION PREVENTS LETHAL GRAFT-VERSUS-HOST DISEASE WHILE MAINTAINING ANTITUMOR IMMUNITY
EHA Learning Center, Zachariah McIver, 215787
AN UNBALANCED MONOCYTE MACROPHAGE POLARIZATION IN THE BONE MARROW MICROENVIRONMENT MAY CAUSE THE OCCURRENCE OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hong-Yan Zhao, 215788
COMMON LINK BETWEEN BONE AND HEART HEALTH IN THALASSEMIA MAJOR.
EHA Learning Center, Alessia Pepe, 215803
CEREBRAL IRON OVERLOAD IN BETA THALASSEMIA: DOES IT REALLY MATTER?
EHA Learning Center, Immacolata Tartaglione, 215805
IMMATURE PLATELET FRACTION: A USEFUL MARKER FOR IDENTIFYING THE CAUSE OF THROMBOCYTOPENIA AND PREDICTING PLATELET RECOVERY
EHA Learning Center, Eunyup Lee, 215820
PLATELETPHERESIS-ASSOCIATED LYMPHOPENIA IN FREQUENT PLATELET DONORS
EHA Learning Center, John Gansner, 215821
ENHANCED BONE MARROW HOMING OF NATURAL KILLER CELLS FOLLOWING MRNA TRANSFECTION WITH GAIN-OF-FUNCTION CXCR4
EHA Learning Center, Emily Levy, 215900
INTERLEUKIN-15-CULTURED DENDRITIC CELLS ENHANCE ANTI-TUMOR GAMMA DELTA T CELL FUNCTIONS THROUGH IL-15 SECRETION
EHA Learning Center, Heleen Van Acker, 215901
LABORATORY CHARACTERIZATION OF PATIENTS WITH (SUSPECTED) INHERITED PLATELET DISORDERS: RESULTS FROM THE ‘THROMBOCYTOPATHY IN THE NETHERLANDS’ STUDY
EHA Learning Center, Maaike Blaauwgeers, 215916
A DECREASED PLATELET-TO-LYMPHOCYTE RATIO IS ASSOCIATED WITH A LOW PLATELETCRIT IN PRE-DIABETES
EHA Learning Center, Bongani Nkambule, 215917

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings